Patients with myelofibrosis (MF) who took ruxolitinib experienced greater symptom score reduction than those receiving momelotinib in a study involving 432 individuals. Participants with high risk, intermediate-2 risk, or symptomatic intermediate-1 risk MF were randomly assigned to receive either ruxolitinib 20 mg twice a day (or per label) or momelotinib 200 mg once daily for 24 weeks. End points evaluated included spleen volume reduction, response, and adverse events. Among the results:

• A ≥50% reduction in the total symptom score was seen in 42% of patients taking ruxolitinib, vs 28% in those receiving momelotinib.
• Spleen volume reduction rates at 24 weeks were 29% and 24%, respectively.
• Grade ≥3 infections occurred in 3% and 7%, respectively.
• Treatment-emergent peripheral neuropathy occurred in 5% and 10%, respectively.